The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Malhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B. (1995) · Nature Medicine · doi:10.1038/nm0395-237 · Cited by 786
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“cellular cytotoxicity (ADCC) (667–670) (671) that are relevant to biotechnology (672, 673).”
BackgroundThe etiology of rheumatoid arthritis
Scherer, H. U., Häupl, T., & Burmester, G. R. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102400 · Cited by 881
A systematic approach to protein glycosylation analysis: a path through the maze
Mariño, K., Bones, J., Kattla, J. J., & Rudd, P. M. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.437 · Cited by 628
A Functional Role for Antibodies in Tuberculosis
Lu, L. L., Chung, A. W., Rosebrock, T. R., Ghebremichael, M., Yu, W. H., Grace, P. S., Schoen, M. K., Tafesse, F., Martin, C., Leung, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.072 · Cited by 571
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Endoplasmic Reticulum Stress in Immunity
Bettigole, S. E., & Glimcher, L. H. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112116 · Cited by 513
Karsten, C. M., Pandey, M. K., Figge, J., Kilchenstein, R., Taylor, P. R., Rosas, M., McDonald, J. U., Orr, S. J., Berger, M., Petzold, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2862 · Cited by 479
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Ackerman, M. E., Moldt, B., Wyatt, R. T., Dugast, A.-S., McAndrew, E., Tsoukas, S., Jost, S., Berger, C. T., Sciaranghella, G., Liu, Q., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.12.016 · Cited by 450
Human plasma protein N-glycosylation
Clerc, F., Reiding, K. R., Jansen, B. C., Kammeijer, G. S. M., Bondt, A., & Wuhrer, M. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-015-9626-2 · Cited by 450
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Advances in recombinant antibody manufacturing
Kunert, R., & Reinhart, D. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7388-9 · Cited by 417
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Higel, F., Seidl, A., Sörgel, F., & Friess, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.005 · Cited by 360
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Rombouts, Y., Ewing, E., van de Stadt, L. A., Selman, M. H. J., Trouw, L. A., Deelder, A. M., Huizinga, T. W. J., Wuhrer, M., van Schaardenburg, D., Toes, R. E. M., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203565 · Cited by 288
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
“However, because highmannose structures are not fucosylated in the core region, the observed effects may be due to the absence of core fucose rather than the presence of high mannose.(147) According to some authors, high mannose forms of Fc-glycosylated immunoglobulins are removed from the circulation through binding…”
BackgroundInfluentialFc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
“Our observations for core defucosylation were supported by many previous studies investigating both heterogeneous and homogeneous glycoforms.(12,13,22,34-42) However, no consensus Figure 8.”
BackgroundMethodJimenez del Val, I., Nagy, J. M., & Kontoravdi, C. (2011) · Biotechnology Progress · doi:10.1002/btpr.688 · Cited by 135
“Many studies have found that the oligosaccharides attached to these sites greatly influence the efficacy of mAbs as therapeutics either by reducing their serum halflife(3,4) or by directly affecting the therapeutic mechanisms they trigger in the patient.(2,5) mAbs are produced industrially by culturing mammalian cells…”
BackgroundChung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z. J., Shen, A., et al. (2012) · mAbs · doi:10.4161/mabs.19941 · Cited by 127
Multi-angle effector function analysis of human monoclonal IgG glycovariants
Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143520 · Cited by 101
Antibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95
Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies
Yu, X., Baruah, K., Harvey, D. J., Vasiljevic, S., Alonzi, D. S., Song, B.-D., Higgins, M. K., Bowden, T. A., Scanlan, C. N., & Crispin, M. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4014375 · Cited by 84
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Park, J. H., Noh, S. M., Woo, J. R., Kim, J. W., & Lee, G. M. (2016) · Biotechnology Journal · doi:10.1002/biot.201500327 · Cited by 81
Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid
Yehuda, S., & Padler-Karavani, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00021 · Cited by 71
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
Lee, C., Jeong, M., Lee, J. J., Seo, S., Cho, S. C., Zhang, W., & Jaquez, O. (2017) · mAbs · doi:10.1080/19420862.2017.1337620 · Cited by 57
Impact of Fc N-glycan sialylation on IgG structure
Zhang, Z., Shah, B., & Richardson, J. (2019) · mAbs · doi:10.1080/19420862.2019.1655377 · Cited by 46
del Val, I. J., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.09.005 · Cited by 45
Ha, T. K., Hansen, A. H., Kildegaard, H. F., & Lee, G. M. (2019) · Biotechnology Journal · doi:10.1002/biot.201900130 · Cited by 30
Production of Highly Sialylated Monoclonal Antibodies
Raymond, C., Robotham, A., Kelly, J., Lattova, E., Perreault, H., & Durocher, Y. (2012) · Glycosylation · doi:10.5772/51301 · Cited by 20
“The first and second GlcNAc residues generate H-bonds with Asp265 and Arg301 respectively [6].”
BackgroundInfluentialBheemareddy, B. R., Pulipeta, M., Iyer, P., & Dirisala, V. R. (2019) · Journal of Carbohydrate Chemistry · doi:10.1080/07328303.2018.1541995 · Cited by 7
Metadata
- Authors
- Raju, T. S.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 20
- Issue
- 4
- Pages
- 471-478
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W2136007354
- Cited by
- 521
- References
- 49
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.